Finasteride Side Effects: The Honest Guide

Finasteride is a competitive and specific inhibitor of Type II 5α-reductase, the intracellular enzyme that converts testosterone into DHT^[1]. In men with male pattern hair loss, the finasteride 1 mg labeling states that the balding scalp contains miniaturized hair follicles and increased amounts of DHT compared with hairy scalp, and that finasteride decreases scalp and serum DHT concentrations in these men^[1]. Finasteride 1 mg (the brand-name product Propecia®) is FDA-labeled for the treatment of male pattern hair loss (androgenetic alopecia) in men only^[1].

Its most discussed side effects are sexual. The honest version of those numbers is printed on the finasteride labeling itself, and almost nobody quotes it. This guide does — because you cannot give informed consent to a risk nobody quantified for you.

One distinction to hold onto first: finasteride is sold as two different products, at two different doses, for two different conditions. Finasteride 1 mg is labeled for male pattern hair loss^[1]; finasteride 5 mg (Proscar®) is labeled for benign prostatic hyperplasia (BPH)^[2]. Their adverse-reaction rates are not the same, and the internet routinely quotes the 5 mg numbers at men considering the 1 mg tablet. Every rate below names its dose.

The sexual side effects, by the actual numbers

In three controlled 12-month trials of finasteride 1 mg, the labeling reports the drug-related adverse experiences in year 1 as: decreased libido 1.8% on finasteride versus 1.3% on placebo; erectile dysfunction 1.3% versus 0.7%; and ejaculation disorder 1.2% versus 0.7%^[1]. An integrated analysis in that same labeling found that 36 of 945 men (3.8%) taking finasteride 1 mg reported one or more of these adverse experiences, compared with 20 of 934 men (2.1%) on placebo (p=0.04)^[1].

That is the “roughly 4 in 100 versus 2 in 100” figure, and it is worth knowing precisely. It is not nothing, and it is not the near-certainty that alarmist forums imply. The finasteride 1 mg labeling also reports that 1.4% of men taking finasteride discontinued because of drug-related adverse experiences, versus 1.6% on placebo^[1], and that the incidence of each of those adverse experiences decreased to ≤0.3% by the fifth year of treatment^[1].

On whether they go away, the finasteride 1 mg labeling says this exactly: “Resolution occurred in men who discontinued therapy with PROPECIA due to these side effects and in most of those who continued therapy.”^[1] That is the labeling's own sentence, and it is narrower than the reassurance you will read elsewhere — it is not a guarantee that every effect resolves in every man. The persistence reports below are exactly why that distinction matters.

For contrast, at the 5 mg BPH dose the rates run higher: the finasteride 5 mg labeling reports year-1 impotence at 8.1% versus 3.7% on placebo, and decreased libido at 6.4% versus 3.4%^[2]. In years 2 through 4 of that same study, the finasteride 5 mg labeling states there was no significant difference between treatment groups in the incidences of impotence, decreased libido and ejaculation disorder^[2].

The persistence reports, and the honest uncertainty

This is where an honest guide has to resist tidying things up. The finasteride 1 mg labeling's postmarketing section lists “sexual dysfunction that continued after discontinuation of treatment, including erectile dysfunction, libido disorders, ejaculation disorders, and orgasm disorders”^[1]. The reports are real enough to appear on the FDA-approved labeling.

But that labeling attaches its own limit to the section: these reactions are “reported voluntarily from a population of uncertain size,” so “it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure”^[1]. In plain terms — the labeling records that men reported it; the labeling does not tell you how often it happens, or that finasteride caused it.

The published literature presses harder than the labeling does, and it is not settled. A 2020 review in Fertility and Sterility describes post-finasteride syndrome (PFS) as persistent sexual, neurological, physical and mental effects developing during or after finasteride treatment, states that there are to date no evidence-based effective treatments for it, and notes that “the medical community has yet to recognize this syndrome”^[4]. That review's author concludes that finasteride induces a constellation of persistent adverse effects in a subset of men — while also noting that many clinical studies suffer from incomplete or inadequate assessment of adverse events and limited reporting of harm^[4].

So, squarely: the labeling records the reports without estimating their frequency or establishing causation^[1]; a peer-reviewed review argues the syndrome is real in a subset of men, while acknowledging the medical community has not recognized it and that the underlying harms data is often incomplete^[4]. We are not going to tell you it is definitely nothing, and we are not going to tell you it is common. Both would be dishonest — and the two sources above are precisely why neither sentence can be written.

Mood matters too

The finasteride 1 mg labeling lists depression, and suicidal ideation and behavior, under its postmarketing Nervous System/Psychiatric reactions^[1] — carrying the same stated limitation as above: voluntary reports, with frequency and causality not established^[1].

The literature has tried to put numbers to the depression question. A 2021 systematic review and meta-analysis found crude pooled rates of depressive symptoms of 3.33% (confidence interval 3.22%–3.44%) with finasteride versus 2.54% (2.44%–2.64%) without, and a random-effects odds ratio of 2.14 (1.40–3.27), P < 0.0001^[3]. Its stated conclusion: “The findings support a growing impression that finasteride is associated with adverse psychiatric effects that can persist in association with sexual dysfunction after discontinuing finasteride treatment.”^[3]

If your mood shifts while on treatment, tell your medical provider promptly — this is not something to tough out. And if you are struggling right now, call or text 988, the Suicide & Crisis Lifeline, any hour. Naming this plainly is part of the honest version; a hair-loss decision should never cost more than the hair.

Why men quit — and what quitting does

Men stop finasteride for a few reasons: a side effect they do not want to live with, anxiety fed by what they read online, or simple fatigue with a daily pill. That is a legitimate personal choice. But here is the trade-off almost no product page prints — and it is stated flatly on the labeling: “Withdrawal of treatment leads to reversal of effect within 12 months.”^[1] The same labeling states that continued use is recommended to sustain benefit, and that the benefit should be re-evaluated periodically^[1].

The trial data behind that sentence: among men switched from finasteride 1 mg to placebo (n=48) at the end of the initial 12 months, the labeling reports reversal of the increase in hair count 12 months later, at 24 months^[1]. Finasteride does not cure the underlying process — it holds it back. That is not a subscription trick; it is what the labeling says the biology does. Knowing it changes the question from “should I take a pill” to “am I willing to maintain this,” which is the real decision.

The rest of the honest list

PSA — and a number that gets misquoted. In clinical studies of finasteride 1 mg in men 18–41 years of age, the labeling reports that the mean value of serum PSA decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12^[1]. The widely repeated “finasteride halves your PSA” actually belongs to the other product: finasteride 5 mg reduced serum PSA concentration by approximately 50% within six months of treatment in men with BPH^[2][1]. Either way, the finasteride 1 mg labeling directs that any confirmed increase from the lowest PSA value while on treatment may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5α-reductase inhibitor^[1]. Your medical provider needs your finasteride use on record so your results are read correctly.

High-grade prostate cancer. The finasteride 1 mg labeling carries this warning: in the 7-year Prostate Cancer Prevention Trial, men aged 55 and over with a normal digital rectal examination and PSA ≤3.0 ng/mL who took finasteride 5 mg/day — five times the hair-loss dose — had an increased risk of Gleason score 8–10 prostate cancer, 1.8% versus 1.1% on placebo^[1].

Exposure risk to a male fetus. Women should not handle crushed or broken finasteride 1 mg tablets when they are pregnant or may potentially be pregnant, because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus^[1]. The labeling notes that finasteride 1 mg tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed^[1].

Breast changes. Breast tenderness and enlargement, and male breast cancer, appear in the finasteride 1 mg postmarketing list^[1]. On the larger question the labeling is candid: “The relationship between long-term use of finasteride and male breast neoplasia is currently unknown.”^[1] Report any breast lump, pain, enlargement or nipple discharge to your medical provider.

How to decide well

A good decision here is not “is finasteride safe” in the abstract — it is “is this trade-off right for me, right now.” That is exactly the judgment a medical provider is for. Our hair loss program puts your case in front of a provider licensed in your state, who weighs your pattern of loss, your history, and your tolerance for the risks above, and who will tell you if medication is not worth it for your situation. If you are also weighing minoxidil — the other first-line option, with a very different side-effect profile — the oral-versus-topical minoxidil guide covers it, and the full menu of options and prices sits on the hair loss page.

FAQ

Will finasteride wreck my sex life?

For most men in the trials, no. In the finasteride 1 mg trials, an integrated analysis found that 36 of 945 men (3.8%) reported one or more sexual adverse experiences, versus 20 of 934 (2.1%) on placebo, p=0.04^[1]. The labeling adds that the incidence of each of those experiences decreased to ≤0.3% by the fifth year of treatment^[1]. The risk is real and worth taking seriously, but the common online framing that it is likely is not what the labeled trial data shows.

Are the side effects permanent?

The finasteride 1 mg labeling states that “Resolution occurred in men who discontinued therapy with PROPECIA due to these side effects and in most of those who continued therapy”^[1]. But that same labeling separately lists, under postmarketing reports, sexual dysfunction that continued after discontinuation of treatment^[1] — while cautioning that such voluntary reports cannot reliably establish frequency or causation^[1]. A 2020 review argues those persistent effects are real in a subset of men, and notes the medical community has yet to recognize the syndrome^[4]. The honest answer: for most men in the trials the effects resolved, a subset of men report that they did not, and the question is not settled. You deserve to know those reports exist before the first tablet, not after.

Should I stop if I notice something?

Tell your medical provider promptly rather than deciding alone. Some effects settle; some warrant stopping. And if your mood shifts, raise it right away — the finasteride 1 mg labeling lists depression, and suicidal ideation and behavior, among its postmarketing reports^[1]. If you are struggling now, call or text 988, any hour.

Does finasteride affect my prostate or PSA test?

Yes. At the 1 mg hair-loss dose, mean serum PSA decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12 in men 18–41^[1]; the approximately 50% reduction usually quoted comes from the 5 mg BPH dose^[2][1]. Any confirmed increase from your lowest PSA value while on finasteride should be evaluated, even if it is still within the normal range^[1]. Make sure your finasteride use is on your record before a PSA test.

Is compounded topical finasteride the same thing?

No. The FDA-approved finasteride labeling covers tablets for oral use in men^[1]. A compounded topical preparation containing finasteride is a different, non-FDA-approved preparation, and the trial numbers on this page come from the FDA-approved oral products that were studied — they do not transfer to compounded formulations.

Related guide: Oral vs. Topical Minoxidil for Men

This guide is general information, not medical advice, and describes no guaranteed outcome. Finasteride 1 mg is an FDA-approved oral medication (the generic of Propecia®); a compounded topical that contains finasteride is a different, non-FDA-approved preparation. Finasteride can cause sexual side effects^[1], and its labeling lists depression, and suicidal ideation and behavior, among postmarketing reports^[1]; it lowers PSA test results^[1]; women who are or may become pregnant should not handle crushed or broken tablets^[1]. Individual results vary, and the labeling states that withdrawal of treatment leads to reversal of effect within 12 months^[1]. Whether treatment is appropriate is decided by a medical provider licensed in your state. If you are struggling with low mood or thoughts of self-harm, call or text 988 (Suicide & Crisis Lifeline), any hour; in a medical emergency, call 911.